Standout Papers

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-bli... 2017 2026 2020 2023 519
  1. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial (2017)
    Stewart J. Tepper, Messoud Ashina et al. The Lancet Neurology
  2. Migraine (2020)
    Messoud Ashina New England Journal of Medicine
  3. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine (2018)
    David W. Dodick, Messoud Ashina et al. Cephalalgia
  4. Migraine: epidemiology and systems of care (2021)
    Messoud Ashina, Zaza Katsarava et al. The Lancet
  5. Migraine and the trigeminovascular system—40 years and counting (2019)
    Messoud Ashina, Jakob Møller Hansen et al. The Lancet Neurology
  6. Migraine (2022)
    Michel D. Ferrari, Peter J. Goadsby et al. Nature Reviews Disease Primers
  7. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial (2019)
    Michel D. Ferrari, Hans‐Christoph Diener et al. The Lancet
  8. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults (2018)
    Cristina Tassorelli, Hans‐Christoph Diener et al. Cephalalgia
  9. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) (2020)
    Messoud Ashina, Joel R. Saper et al. Cephalalgia
  10. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention (2019)
    Simona Sacco, Lars Bendtsen et al. The Journal of Headache and Pain
  11. Migraine: disease characterisation, biomarkers, and precision medicine (2021)
    Messoud Ashina, Gisela M. Terwindt et al. The Lancet
  12. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update (2022)
    Simona Sacco, Faisal Mohammad Amin et al. The Journal of Headache and Pain
  13. Migraine: integrated approaches to clinical management and emerging treatments (2021)
    Messoud Ashina, Dawn C. Buse et al. The Lancet
  14. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (2023)
    Patricia Pozo‐Rosich, Jessica Ailani et al. The Lancet
  15. A Monoclonal Antibody to PACAP for Migraine Prevention (2024)
    Messoud Ashina, Ioana Florea et al. New England Journal of Medicine

Immediate Impact

15 from Science/Nature 88 standout
Sub-graph 1 of 19

Citing Papers

Human assembloid model of the ascending neural sensory pathway
2025 StandoutNature
Nociceptive neurons promote gastric tumour progression via a CGRP–RAMP1 axis
2025 StandoutNature
34 intermediate papers

Works of Messoud Ashina being referenced

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
2019 Standout
No increase of calcitonin gene–related peptide in jugular blood during migraine
2005
and 23 more

Author Peers

Author Last Decade Papers Cites
Messoud Ashina 15761 8813 6113 428 18.9k
Rami Burstein 14171 7524 6922 192 18.2k
Stephen D. Silberstein 20708 13188 9332 426 25.2k
David W. Dodick 22431 14568 9024 526 27.5k
Giuseppe Nappi 9559 5169 5602 595 19.2k
Jean Schoenen 10973 6675 4734 407 15.3k
Michel D. Ferrari 21217 10711 7471 522 29.0k
Marcelo E. Bigal 14785 8648 5327 268 16.9k
Cristina Tassorelli 6649 3319 2937 395 11.2k
Rigmor Jensen 12942 7638 6198 395 18.4k
Gisela M. Terwindt 7177 3133 2036 243 10.0k

All Works

Loading papers...

Rankless by CCL
2026